Semaglutide vs Tirzepatide: Which Is Better for Weight Loss?

Semaglutide vs Tirzepatide: Which Leads to More Weight Loss?

Which leads to greater weight loss: semaglutide or tirzepatide? This semaglutide versus tirzepatide weight loss comparison matters if you are starting or continuing GLP-1 therapy. The two medicines differ in average weight loss, speed of response, and common side-effect patterns. Those differences affect how quickly you see results and how tolerable the routine feels. This section gives a practical framework to read trial numbers and weigh real-world data.

Tracking matters. Knowing dates, doses, weight, and symptoms helps you compare outcomes to published averages. Use a single organized record so you can spot trends and share clear notes with your clinician. Pepio helps you keep the routine organized without extra complexity. People using Pepio find it easier to review dose history and symptom patterns between visits. Read on for data highlights, comparison guidance, and tracking tips you can use today.

How to Compare Weight‑Loss Results: Key Criteria

When comparing semaglutide and tirzepatide for weight loss, use clear, measurable criteria. The phrase "comparison metrics for semaglutide vs tirzepatide" means the objective metrics and data sources you should use to judge which drug fits your goals. These criteria help you translate trial averages into personal progress.

• Percentage of body weight lost at the usual endpoints (68–72 weeks)
• Time to reach common milestones (5%, 10% loss)
• Side‑effect profile and its impact on adherence
• Adherence and dropout rates in trials and real‑world cohorts
• Type of evidence: randomized trials vs meta‑analyses vs registry data

Start with percent weight loss at standard endpoints. Trials and pooled analyses report percent changes at roughly 68–72 weeks. A 2025 meta‑analysis found tirzepatide had about a 4.23% greater mean weight‑loss advantage versus semaglutide across pooled RCTs (meta‑analysis). Time to milestone matters too. For example, many analyses show tirzepatide reaches 5% weight loss faster than semaglutide (≈8 weeks to 5% for tirzepatide vs ≈12 weeks for semaglutide in trial analyses) (JAMA analysis).

Assess side effects and tolerability. Side‑effect frequency and severity shape real‑world effectiveness because they affect whether people keep taking the drug. Network comparisons also show tirzepatide outperforming semaglutide on weight and A1c, which factors into benefit‑risk tradeoffs (network meta‑analysis).

Look at adherence and dropout rates from both trials and registries. Randomized trials give controlled efficacy, head‑to‑head trials show direct comparisons, and meta‑analyses pool effects across studies. Real‑world cohorts illustrate how tolerability and access affect outcomes outside trials.

Finally, consistent self‑tracking makes these criteria useful for you. Pepio helps you keep clear dose, weight, and symptom records so you can compare your personal progress against published metrics. Users who organize logs using Pepio can more easily map their timeline to trial endpoints and discuss trends with clinicians. Learn more about Pepio’s approach to tracking weight‑loss progress and how organized records make comparisons more meaningful.

Pepio GLP‑1 Tracker: Your Edge in Measuring Weight‑Loss Success

To compare semaglutide and tirzepatide fairly, you need precise, time‑linked measures: percent weight loss, time to milestones, adherence, and side effects. Structured tracking ties those measures to exact dose dates, symptom timing, and weight entries so patterns are visible. Pepio weight loss tracking benefits compared to semaglutide and tirzepatide include clearer timing, adherence insight, and easier clinician summaries.

Pepio helps you collect those data points in one place so you can map outcomes to real events. Users using Pepio experience clearer timelines that make it easier to see whether a weight change follows a dose, a dose increase, or a missed shot.

• Log dose, date, injection site, and symptoms
• View automatic weight‑loss and symptom trend charts tied to dose history (feature of the Pepio iOS app)
• Export summaries to share with your clinician
• Use free web tools (no sign‑up; local browser storage): calculators, the GLP‑1 shot tracker (with CSV export), symptom log, injection site‑rotation planner, titration schedules, and next‑dose date calculator

The Pepio iOS app also offers iOS‑only push‑notification reminders and a clinician‑ready PDF export to simplify follow‑ups.

Linking weight entries with dose history shows when percent loss accelerates after a schedule change. Logging symptoms and appetite (food‑noise) alongside dates helps separate side effects from unrelated events. Exportable summaries let you bring concise records to follow‑ups, saving time for both you and your clinician.

Research supports this approach. Digital engagement and consistent logging associate with larger weight losses (Impact of Digital Engagement on Weight Loss Outcomes in Obesity – NCBI). A 12‑month cohort found adherent users lost 22.6% mean body weight versus 13.6% for non‑adherent users (MDPI). Two‑year persistence data show low long‑term adherence, highlighting the need for routine support (Prime Therapeutics). App‑based behavioral support also helped patients reach similar weight loss with lower drug doses, reducing medication cost (TCTMD).

Trackers are not a substitute for clinical guidance. Pepio organizes your dose history, symptoms, and weight trends for clearer interpretation. It does not provide dosing advice; always follow your clinician, prescriber, pharmacist, or medication label.

Learn more about how Pepio's approach to GLP‑1 tracking helps you measure semaglutide and tirzepatide results, prepare notes for visits, and stay consistent.

Semaglutide: Clinical Trial Weight‑Loss Outcomes

Semaglutide has produced consistent, sizable weight loss in randomized trials. The phrase "semaglutide weight loss results in clinical trials" reflects many studies showing mean reductions well above typical lifestyle changes. Across the STEP program, adults treated with semaglutide 2.4 mg lost about 15–17% of body weight after 68 weeks (STEP 1 trial). A large cardiovascular-outcomes study reported that 67.8% of participants reached at least 5% weight loss, and 44.2% reached at least 10% after 104 weeks on semaglutide 2.4 mg (SELECT trial). Pepio’s tracking helps you see where you land relative to these longer-term benchmarks. Shorter studies show meaningful early change. One 26-week study found roughly a 10% mean weight reduction, about 10.5 kg on average (6-month study). Longer follow-up in STEP‑5 demonstrated durable reductions, with a mean 15.2% loss at 104 weeks compared with placebo (STEP‑5 results). Median time to a 5% loss in the STEP trials was about 12 weeks (press summary).

• Average ~15–17% body-weight loss at ~68 weeks (STEP trials)
• 67.8% achieved ≥5% loss and 44.2% ≥10% loss in SELECT (104 weeks)
• ~10% mean weight reduction at 26 weeks in some studies (~10.5 kg)
• Nausea (~30%) and vomiting (~15%) early in treatment; tracking symptoms can help manage adherence

Early gastrointestinal effects were common in trials. Nausea affected roughly 30% of participants, and vomiting about 15% during the first 12 weeks in several studies (STEP trials summary). These side effects often lessened with time and dose escalation, but they can affect adherence. Monitoring symptoms alongside dose timing helps explain individual differences in weight response.

Because trial averages do not predict any single person's course, track your weight and symptoms regularly. Pepio helps people keep dose history, weight, and symptom notes together so trends are easier to spot. Many users find that organized records make it simpler to discuss progress with clinicians. Learn more about Pepio's approach to tracking GLP‑1 routines and how organized self‑tracking can clarify your individual response. Pepio is for organization and self‑tracking only. Pepio does not provide medical advice, dosing recommendations, or treatment guidance. Always follow instructions from your clinician, prescriber, pharmacist, or medication label.

Tirzepatide: Real‑World Weight‑Loss Performance

Real‑world and trial data show tirzepatide often produces larger, faster weight loss than single‑agonist GLP‑1s. Several head‑to‑head trials and registries report consistently greater mean reductions with tirzepatide versus semaglutide and earlier GLP‑1 agents. The SURPASS‑2 randomized trial found tirzepatide 15 mg resulted in nearly double the mean weight loss of semaglutide 1 mg (≈12 kg vs ≈6 kg) NEJM Trial – Tirzepatide vs Semaglutide (2021). Real‑world cohorts reinforce those findings. Some registries report roughly a 20% average body‑weight reduction at about 72 weeks in tirzepatide‑treated adults with obesity or type 2 diabetes (Real‑World Effectiveness of Tirzepatide versus Semaglutide, 2025). A multi‑center registry showed one‑year mean losses of –17.2 kg with tirzepatide versus –14.6 kg with semaglutide 2.4 mg (PMC, 2025). Tirzepatide also tends to reach early milestones faster. Comparative analyses found a ≈5% weight‑loss threshold around eight weeks on tirzepatide, versus about twelve weeks on semaglutide (JAMA Internal Medicine – Semaglutide vs Tirzepatide, 2024). Early routine reports describe a relatively rapid initial response in many patients, though reported weekly weight‑loss rates vary by cohort and baseline weight. Gastrointestinal side effects are common and worth tracking. Studies report nausea, vomiting, and diarrhea in approximately 30–35% of tirzepatide patients. Reported discontinuation rates vary by cohort and follow‑up and are often higher than 5% in real‑world settings; some cohorts report discontinuation in the ~10–20% range (Real‑World Effectiveness of Tirzepatide versus Semaglutide, 2025). Individual tolerance varies, so monitoring symptoms alongside weight change matters.

• ≈20% average body‑weight reduction at ~72 weeks in some real‑world cohorts and trials
• Faster early response: ~5% loss in ~8 weeks vs ~12 weeks for semaglutide
• Higher incidence of GI side effects (nausea, diarrhea) reported in ~30–35% of patients; reported discontinuation rates vary by cohort and follow‑up and are often higher than 5% (some cohorts report ~10–20%)
• Head‑to‑head trials and meta‑analyses show tirzepatide often produces a several‑percentage‑point greater mean loss vs semaglutide

Interpreting these averages requires individual tracking of symptoms, appetite or food‑noise, and weight trends. Pepio helps users keep that context together so changes in early response or side effects are easier to review with a clinician. Using Pepio’s iOS reminders alongside dose history and symptom logging makes it simpler to track adherence and tolerance over time. Users tracking dose history, symptoms, and weight with Pepio can spot patterns and prepare clearer visit notes. Learn more about Pepio’s practical approach to tracking GLP‑1 progress and how organized records make follow‑up conversations more productive. Pepio is for organization and self‑tracking only. Always follow instructions from your clinician, prescriber, pharmacist, or medication label.

Quick Comparison: Semaglutide vs Tirzepatide vs Pepio Tracking

Trials and a 2025 meta‑analysis consistently show tirzepatide produces larger average weight loss than semaglutide (PMC meta‑analysis, 2025; EMPR News). Faster time to 5% weight loss was highlighted in the JAMA analysis (JAMA Internal Medicine). Real‑world data broadly reflect these trial differences (Springer real‑world analysis, 2025). Pepio helps you log doses, weight, and GI symptoms so you can see how trial‑level differences play out in your own data. Learn how Pepio’s tracking approach can make dose history, symptom notes, and weight trends easy to review before a clinician visit.

Tirzepatide tends to produce larger, faster average weight loss than semaglutide in clinical trials and real‑world studies. Head‑to‑head and pooled analyses support that pattern (NEJM trial; a recent meta‑analysis found similar results (PMC meta‑analysis)). Individual response and tolerability still vary widely.

Tracking your routine makes those differences clear. Pepio helps you record doses, symptom timing, and weight trends so you can see what actually happens for you. Users report cleaner dose histories and easier note‑sharing with clinicians, which helps focus follow‑up conversations.

If you want to compare progress rather than guess, learn more about Pepio’s approach to organized GLP‑1 and peptide tracking. Pepio is for organization and self‑tracking only. Pepio does not provide medical advice, diagnosis, or dosing guidance — always follow your clinician, prescriber, pharmacist, or medication label.